Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …

Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with
surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and …

In the last decade, immune-checkpoint inhibitors (ICIs) have become the backbone of
therapy in advanced, non-oncogene driven, non-small cell lung cancer (NSCLC). More …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of
patients with locally advanced unresectable and metastatic non-small cell lung cancer …

PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …

8521 Background: The combination of chemotherapy and immunotherapy (CT-IO) has a
high response rate and longer survival in unselected patients (pts) with metastatic non-small …

Lung cancer is the predominant cause of cancer-related deaths globally, with non-small cell
lung cancer (NSCLC) accounting for 85% of all cases. 1 The five-year overall survival (OS) …

Approximately a third of patients with non-small-cell lung cancer (NSCLC) present with
surgically resectable disease. Patients who undergo surgical resection are at a high risk of …

Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …